Session » Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes
-
Abstract Number: 2253
Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture
-
Abstract Number: 2254
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
-
Abstract Number: 2255
Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
-
Abstract Number: 2256
Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study
-
Abstract Number: 2257
How Does Non-Compliance to Prolia ® (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients?
-
Abstract Number: 2259
Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
-
Abstract Number: 2260
Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients
-
Abstract Number: 2261
A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis
-
Abstract Number: 2262
Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases
-
Abstract Number: 2263
Continued Zoledronic Acid Use in a Large Healthcare System
-
Abstract Number: 2264
Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
-
Abstract Number: 2265
Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients
-
Abstract Number: 2266
Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis